Celltech Finds CDP-870 Partner In UCB; BLA Filing Expected By 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.
You may also be interested in...
UCB/Celltech Merger Nears Completion: Integration To Commence Under CEO Doliveux
Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.
UCB/Celltech Merger Nears Completion: Integration To Commence Under CEO Doliveux
Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.
Celltech Codeprex Approved For 12-Hour Cough Suppression
Celltech expects the codeine-based antitussive to hit retail pharmacy shelves by the fourth quarter. The extended-release formulation eliminates the need for middle of the night dosing, the company says.